



Annual Meeting of the European Teratology Society (ETS)
Elsevier 2020 Award Lecture
September 14, 2021

Molecular Characterization of a Toxicological Tipping Point during Human Stem Cell Differentiation

USEPA – Office of Research and Development
Center for Computational Toxicology and Exposure
Chemical Safety for Sustainability (CSS) Research Program

Research Triangle Park, NC 27711

knudsen.thomas@epa.gov

*DISCLAIMER: The views expressed are those of the presenters
and do not reflect Agency policy.*



Project Team



Kate Saili, PhD
Postdoctoral Fellow
(now *OAR-OAQPS*)
Lead author



Imran Shah, PhD
CCTE
Computational Biologist
Tipping points



Todor Antonijevic, PhD
Postdoctoral Fellow
(now *ToxStrategies*)
Boolean analysis



Chad Deisenroth, PhD
CCTE
Cell Biologist
High content imaging



Todd Zurlinden, PhD
Postdoctoral Fellow
(now *ORD-CPHEA*)
Bioinformatics



Tom Knudsen, PhD
CCTE
Developmental Biologist
Corresponding author



Vala Sciences, Inc. performed the chemical exposures and sample collection under U.S. Environmental Protection Agency contract #EPD13054.

Subcontractor: human iPSC line from Allele Biotechnology and Pharmaceuticals, Inc.



Subcontractor: Cofactor Genomics performed the library construction and RNA-sequencing.



Thanks to David Belair, Logan Everett, John Cowden, and RTX reviewers for helpful comments on the manuscript.


New Approach Methods (NAMs)

- NAMs refer to *in vitro* data and *in silico* models for toxicological assessment with less reliance on animal testing, thus accelerating data acquisition with fewer resources.
- An explosion of *in vitro* data from high-throughput screening (HTS) and high-content imaging (HCI) enable profiling large chemical libraries for molecular and cellular determinants of bioactivity.
- However, de-scaling the embryo into complex data-sets from *in vitro* profiling brings the challenge of re-composing the full complexity of anatomical development for NAM-based hazard evaluation.
- Dosimetry being a key regulatory driver motivates the need for computational models that can be used to establish a health-protective 'critical response' from complex *in vitro* bioactivity data.




Critical response dosimetry

Point of departure (POD) is the dose at which a biological response is first observed (e.g, LOAEL, BMD₅) and is a basis for reference dose extrapolations in risk assessment.




Toxicological tipping point (TTP) represents the chemical concentration where a biological system (e.g., tissue, organ, or cultured cell) is perturbed beyond its return to homeostasis.



Tipping point: *critical point between adaptive and adverse response trajectories*

- HepG2 is an immortal **endodermal** cell line established from a 15-yr old hepatoma patient.
- HepG2 cells screened with 967 ToxCast chemicals (0.4 to 200 μM) across 6-, 24- and 72-hr.
- Concentration-dependent changes measured by automated HCI on 10 fluorescent labels for:
 - p53 nuclear accumulation
 - stress kinase activation (phospho-JUN)
 - oxidative stress (phospho-H2A.x)
 - cytoskeletal changes (TUBA)
 - mitochondrial polarization (CMXRos)
 - mitochondrial mass (net content)
 - cell cycle arrest
 - mitotic arrest
 - nuclear size
 - cell count

What does a toxicological tipping point look like mathematically?



Goals of this study


Would the TTP model compute a critical response in a differentiating cell lineage?

1. Establish a human iPSC assay for **endoderm** specification and differentiation (endogenesis):

- *Antero-Posterior patterning of definitive endoderm into regional domains (foregut, midgut, hindgut) is locally controlled by mesodermal signals;*
- *all-trans-retinoic acid (ATRA) and various WNT, FGF, and BMP family members recapitulate this progression in hPSC systems.*

2. Explore the 'tipping point' concept in iPSCs directed to endodermal differentiation (with activin) utilizing ATRA as a reference perturbagen.

- *ATRA signaling contributes to endodermal patterning of the gut tube (posteriorizes) and alters SOX17 expression in hPSCs.*
- *SOX17 is a key transcription factor for endodermal patterning, as SOX17-nullizygous mouse embryos lack midgut and hindgut structures.*




ATRA concentration thresholds:

- non-morphogenetic: < 1 nM
- morphogenetic: 3-7 nM
- dysmorphogenic: >30 nM
- broadly teratogenic: >1000 nM

Endogenesis assay

- iPSCs (ABP-SC-HDFAIPS) reprogrammed from adult female fibroblasts.
- Maintained feeder-free in mTeSR medium with ROCK inhibitor.
- Seeded on 384 plates coated with Matrigel (1.5K cells/well); ROCK inhibitor removed at 24h.
- At 48h switched to defined differentiation medium (RPMI-B27 with 100 ng/ml activin).
- ATRA exposure at 0.001, 0.01, 0.1, 1, 10 μ M in 0.1% DMSO, medium renewed daily.
- Cultures processed at 6h, 96h (4-days), or 192h (8-days) for HCl (n=3) and RNAseq analysis (n=2).





HCI analysis: *ATRA-dependent effects on hiPSCs directed to endodermal differentiation*

Concentration-dependent changes over 192h measured in 4 channels (CellProfiler 2.2.0):

FOXA2
Hoechst


- definitive endoderm (FOXA2)
- mitochondria (Mitotracker)
- cell death (ImageIT-Dead)
- cell number (Hoechst)



ATRA concentration response trajectories


- Confluence reached at 96h, but higher cell counts observed with ATRA ≥ 100 nM.
- ATRA suppression of FOXA2-positive cells was significant at 100 nM and higher.
- Non-significant trend on mitochondrial fluorochroming below 10 μ M.
- No effect on cell death below 10 μ M or before 192h.

*ATRA perturbed endogenesis
in a time and concentration dependent manner.*




Transcriptomic response to ATRA exposure

What would the molecular profile of a developmental tipping point look like?

- Total RNA sampled from two biological replicates per treatment.
- cDNA libraries constructed after depleting rRNA and mtRNA contamination. 
- RNA-sequencing 75bp single-end reads >30M read depth on an Illumina NextSeq500.
- Raw and processed data deposited in the Gene Expression Omnibus (GSE131921).
- Reads aligned to the human genome (GRCh38) for Principal Component Analysis (PCA).


PCA of unfiltered count data for 58,051 aligned fragments



* 144h controls because undifferentiated cultures did not survive past 6-days


Differentially Expressed Genes (DEGs)

- 9997 DEGs (median counts > 5, $\text{abs}(\log_2\text{FC}) > 1$, and Benjamini-Hochberg adjustment < 0.05).
- Clustered by gene expression changes in ATRA relative to control samples.
- DEGs resolve to increased (red) and decreased (blue) expression at 96h with ATRA > 10 nM.





Developmental marker genes

- Heat-map of 97 developmental marker genes selected from the literature.
- Covers all three primary germ layers from gastrulation to organogenesis.
- ATRA >10 nM suppressed definitive endoderm (*FOXA2*, *SOX17*, *GATA4*).
- Concomitant increase in primitive streak and mesoderm (*HOXB1*, *HOXB3*, *TBXT*).
- ATRA > 10 nM progressively shifted differentiation toward mesendoderm.



Tipping point computation

- HCl analysis suggested a tipping point between 10 and 100 nM.
- Definitive tipping point was computed on 8340 DEGs at or below 1000 nM ATRA.
- $|X|$ perturbations, V temporality, and $\partial_c V$ concentration derivative.
- TTP = 17 (\pm 11 SD) nM, inferring a critical concentration affecting endogenesis.



ATRA concentration thresholds

Regional and nominal ATRA concentration thresholds reported in different studies on morphogenesis, differentiation, and pregnancy.


Dosimetric	Conc.	Indication	Reference
baseline ATRA (5 somite zebrafish embryo)	< 1 nM	non-morphogenetic	(Shimozono, Imura et al. 2013)
maternal serum (animal study)	1.7 nM	non-teratogenic	(Daston, Beyer et al. 2014)
devTOX ^{qp} assay (pluripotent hESC)	3.0 nM	teratogenic threshold	(Zurlinden, Saili et al. 2020)
normal plasma concentration	5.0 nM	physiological (adult)	(Napoli, Posch et al. 1991)
axial gradient (5 somite zebrafish embryo)	6.0 nM	morphogenetic signal	(Shimozono, Imura et al. 2013)
endodermal differentiation (h-iPSC)	17 nM	toxicological tipping point	(Saili, Antonijevic et al. 2019)
devTOX ^{qp} assay (pluripotent h-iPSC)	19 nM	DevTox potential	(Palmer, Smith et al. 2017)
genetic perturbation (mouse)	30 nM	altered homeostasis	(Helms, Thaller et al. 1994)
maternal serum (animal study)	30 nM	teratogenic potential	(Daston, Beyer et al. 2014)
limb-bud (GD 10.5 mouse embryo)	30 nM	physiological (embryo)	(Horton and Maden 1995)
pharmacological kinetics	1,000 nM	efficacious (therapeutic)	(Helms, Thaller et al. 1994)
limb-bud (GD 11 mouse embryo)	1,500 nM	weakly teratogenic dose	(Satre and Kochhar 1989)
limb-bud (GD 10.5 mouse embryo)	12,500 nM	fully teratogenic dose	(Horton and Maden 1995)

SOURCE: Knudsen et al. (2021), *Reprod Toxicol*

Endodermal trajectories

- ATRA above 17 nM shifts differentiation away from embryonic endoderm in favor of mesoderm (and extraembryonic endoderm).
- The suite of 97 germ layer marker genes (e.g., Fox, Sox, & Hox) captures the shift.
- *In vivo*, ATRA signaling contributes to midgut and hindgut patterning [Bayha et al. (2009) PLoS] ...
- ... *Sox17*-null mice display lethal deficiencies in these endodermal segments [Kanai-Azuma et al. (2002), Development].

ATRA signaling and mesendodermal patterning




Pathway analysis

What pathways might be dysregulated at the tipping point?


- We used Ingenuity Pathway Analysis (IPA) to infer upstream regulators of DEG patterns at 96h.
- *Eomesodermin (EOMES)* emerged as a top candidate for dysregulation at the tipping point.
- *EOMES* is a T-box gene critical for mesendoderm specification at the primitive streak stage.
- IPA predicted a strong inhibition state for EOMES-dependent regulation @ 100 nM ATRA versus a strong activation state in time-matched controls.

Concentration	Upstream Regulator	Expr Log Ratio	Predicted Activation State	Activation z-score	p-value of overlap
DMSO (96h v 6h)	progesterone		Activated	2.148	1.33E-15
DMSO (96h v 6h)	EOMES	6.906	Activated	3.685	7.46E-15
DMSO (96h v 6h)	SOX2	0	Inhibited	-2.731	7.95E-14
DMSO (96h v 6h)	topotecan		Inhibited	-3.923	1.85E-12
DMSO (96h v 6h)	dexamethasone		Activated	3.013	4.58E-12
DMSO (96h v 6h)	tretinoin		Activated	2.51	1.01E-11
0.1 μ M (96h)	EOMES	-1.017	Inhibited	-2.549	1.22E-15
0.1 μ M (96h)	dexamethasone		Inhibited	-2.512	1.62E-13
0.1 μ M (96h)	LHX1	-2.049	Inhibited	-2.774	2.81E-11



Hypothesis

EOMES is central to a tipping point network that accounts for a shift in developmental trajectory of multipotent mesendoderm from endoderm towards mesoderm, which may be linked to ATRA-dependent effects on the Nodal pathway.



Value and Limitations

- This study serves as proof-of-concept that plausible targets in a ‘toxicological tipping point’ can be defined at the molecular level through monitoring regulation of the embryonic transcriptome.
- Although we focused on the influence of ATRA on endogenesis, the approach is scalable to other chemical compounds, cell lineages, and biological processes relevant to hazard evaluation for predictive toxicology.
- Challenges remain for operationalizing this concept in a complex system capable of self-organization (morphogenesis) and canalization (developmental buffering).
- ‘Adaptation’ in this case implies how well a pluripotent system driven toward endodermal differentiation holds to its default trajectory during ATRA exposure, where the tipping point was computed 17 nM.
- ‘Adversity’ implies loss of fault tolerance as the nominal concentration of ATRA led to missing or incorrect cell phenotypes, potentially due to its known effects on cell signaling through the Nodal pathway.
- The findings raise fundamental questions of network dynamics, such as the nature of the primary ‘attractor states’ linked to morphoregulatory pathways.

Thank You!



Kate Saili, PhD
Postdoctoral Fellow
(now *OAR-OAQPS*)
Lead author



Imran Shah, PhD
CCTE
Computational Biologist
Tipping points



Todor Antonijevic, PhD
Postdoctoral Fellow
(now *ToxStrategies*)
Boolean analysis



Chad Deisenroth, PhD
CCTE
Cell Biologist
High content imaging



Todd Zurlinden, PhD
Postdoctoral Fellow
(now *ORD-CPHEA*)
Bioinformatics



Tom Knudsen, PhD
CCTE
Developmental Biologist
Corresponding author



DOI: [10.1016/j.reprotox.2019.10.001](https://doi.org/10.1016/j.reprotox.2019.10.001)